pembrolizumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	04-Oct-24
Call for patient/clinician input closed	02-Dec-24
Submission received	14-Nov-24
Submission accepted	28-Nov-24
Review initiated	29-Nov-24
Draft CADTH review report(s) provided to sponsor for comment	21-Feb-25
Deadline for sponsors comments	04-Mar-25
CDA-AMC review report(s) and responses to comments provided to sponsor	28-Mar-25
Expert committee meeting (initial)	09-Apr-25
Draft recommendation issued to sponsor	23-Apr-25
Draft recommendation posted for stakeholder feedback	01-May-25
End of feedback period	15-May-25

Last Updated : May 1, 2025

lazertinib and amivantamab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	04-Oct-24
Call for patient/clinician input closed	02-Dec-24
Submission received	18-Dec-24
Submission accepted	09-Jan-25
Review initiated	10-Jan-25
Draft CADTH review report(s) provided to sponsor for comment	28-Mar-25
Deadline for sponsors comments	08-Apr-25
CDA-AMC review report(s) and responses to comments provided to sponsor	02-May-25
Expert committee meeting (initial)	14-May-25
Draft recommendation issued to sponsor	May 27, 2025 To May 29, 2025
Draft recommendation posted for stakeholder feedback	05-Jun-25
End of feedback period	19-Jun-25

Last Updated : May 2, 2025

amivantamab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	October 04, 2024
Call for patient/clinician input closed	December 02, 2024
Submission received	February 20, 2025
Submission accepted	March 06, 2025
Review initiated	March 07, 2025
Draft CADTH review report(s) provided to sponsor for comment	May 26, 2025
Deadline for sponsors comments	June 04, 2025
CDA-AMC review report(s) and responses to comments provided to sponsor	June 26, 2025
Expert committee meeting (initial)	July 09, 2025
Draft recommendation issued to sponsor	July 21, 2025 To July 23, 2025
Draft recommendation posted for stakeholder feedback	July 29, 2025
End of feedback period	August 13, 2025

Last Updated : April 17, 2025

Non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation

Details

Review Type: Rapid

Provisional Funding Algorithm
Draft Report Posted:	31-Oct-2024
Stakeholder Feedback Deadline:	7-Nov-2024
Final Report Posted:	5-Dec-2024

Last Updated : December 5, 2024

durvalumab

Details

Submit Feedback

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	02-Oct-24
Call for patient/clinician input closed	25-Nov-24
Submission received	15-Nov-24
Submission accepted	29-Nov-24
Review initiated	02-Dec-24
Draft CADTH review report(s) provided to sponsor for comment	24-Feb-25
Deadline for sponsors comments	05-Mar-25
CDA-AMC review report(s) and responses to comments provided to sponsor	28-Mar-25
Expert committee meeting (initial)	09-Apr-25
Draft recommendation issued to sponsor	24-Apr-25
Draft recommendation posted for stakeholder feedback	01-May-25
End of feedback period	15-May-25

Last Updated : May 1, 2025

Pharmaceutical Reviews Update — Issue 51

Details

Program Updates

1. Update to Ethics Review Component of Complex Reviews

The description of the Ethics Review for Complex Reviews has been updated to further clarify the domains of ethical considerations explored within each review and the use of summary reports where appropriate. The linked Ethics Review Report template has been removed to reflect a customized approach to the reporting of ethical considerations based on the complexity of ethical issues present.

Last Updated : September 26, 2024

delgocitinib

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	September 19, 2024
Call for patient/clinician input closed	November 12, 2024
Submission received	November 25, 2024
Submission accepted	-
Clarification: - Submission was not accepted for review on 09 Dec 2024

Last Updated : April 17, 2025

Adult Classical Hodgkin Lymphoma - Provisional Funding Algorithm - Draft Report - PH0052

isatuximab

Details

Submit Feedback

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	17-Sep-24
Call for patient/clinician input closed	12-Nov-24
Submission received	30-Oct-24
Submission accepted	14-Nov-24
Review initiated	15-Nov-24
Draft CADTH review report(s) provided to sponsor for comment	24-Feb-25
Deadline for sponsors comments	05-Mar-25
CDA-AMC review report(s) and responses to comments provided to sponsor	28-Mar-25
Expert committee meeting (initial)	09-Apr-25
Draft recommendation issued to sponsor	24-Apr-25
Draft recommendation posted for stakeholder feedback	01-May-25
End of feedback period	15-May-25

Last Updated : May 1, 2025

teprotumumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	12-Sep-24
Call for patient/clinician input closed	04-Nov-24
Submission received	25-Oct-24
Submission accepted	08-Nov-24
Review initiated	12-Nov-24
Draft CADTH review report(s) provided to sponsor for comment	07-Feb-25
Deadline for sponsors comments	19-Feb-25
Clarification: - Voluntarily withdrawn by the sponsor

Last Updated : April 24, 2025